pmc logo imageJournal ListSearchpmc logo image
Logo of taosJournal URL: redirect3.cgi?&&auth=0hm9VzA7TFHTV7YFUJroVZYPjEsnEgqu6X0sDB5Wo&reftype=publisher&artid=1312075&article-id=1312075&iid=125076&issue-id=125076&jid=308&journal-id=308&FROM=Article|Banner&TO=Publisher|Other|N%2FA&rendering-type=normal&&http://www.aosonline.org/2001xactions.html
Trans Am Ophthalmol Soc. 1995; 93: 685–708.
PMCID: PMC1312075
The dyschromatopsia of optic neuritis: a descriptive analysis of data from the optic neuritis treatment trial.
B Katz
Abstract
PURPOSE: We sought to characterize the dyschromatopsia of optic neuritis, to determine the type and severity of color defect present and its relation to central vision and spatial acuity, to examine changes in this dyschromatopsia over time, and to determine the applicability of Köllner's rule to patients with optic neuritis. METHODS: We analyzed the raw data on color vision performance as assembled within the Optic Neuritis Treatment Trial (ONTT). The ONTT was designed to evaluate corticosteroids as a treatment for acute demyelinating optic neuritis and to allow long-term outcome and natural history analyses. Between July 1, 1988 and June 30, 1991, 488 patients were enrolled in this trial. All patients underwent extensive neurologic and ophthalmologic examinations including standardized testing of visual function that included testing of color vision. The ONTT population thus afforded a unique opportunity to characterize acquired dyschromatopsias in a large, homogenous, well-characterized cohort of patients with optic neuritis. We used quantitative analysis of FM-100 scores from this patient cohort to determine the severity of the dyschromatopsia, the selectivity of the dyschromatopsia (polarity of errors) and the type of dyschromatopsia (axis of confusion) by employing quadrant analysis of FM-100 scores. RESULTS: The results of high-and low-selectivity analyses of the FM-100 data showed that during the acute phase of optic neuritis, blue/yellow, red/ green, and non-selective color defects occurred; among patients with pure defects, blue/yellow defects were more frequent than red/green defects. At 6 months after the acute event, however, analyses showed that red/green defects were more common than blue/yellow defects. Among patients with selective color defects both acutely and at 6 months, the defect was as likely to change over time as remain the same. The likelihood of persistent dyschromatopsia at 6 months was related to the severity of initial central acuity loss, but the type of dyschromatopsia present (red/green versus blue/yellow) was not. CONCLUSIONS: Our results suggest that at the time of the acute attack of optic neuritis, the majority of selective color defects were blue/yellow defects, whereas at 6 months, more of the selective defects were red/green defects, though both types of defects (as well as nonselective defects) were seen acutely and at 6 months. Despite the rigorous inclusion criteria of the ONTT, the large number of patients we studied, correlation of color vision with visual acuity, and longitudinal follow up, this study showed that no single type of color defect was consistently associated with optic neuritis. Demyelinating optic neuritis does not obey Köllner's rule. Moreover, the type of defect present changed in some patients over the course of recovery. Thus, the type of defect may not even be consistent in individual patients as they recover. The type of defect appeared to be related to spatial vision at the time of the test, but the type of defect present at 6 months was not related to the severity of the initial visual loss. Therefore, in evaluating color defects associated with optic neuritis, the level of central visual function must be considered.
Full text
Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (2.1M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
  • COX, J. Colour vision defects acquired in diseases of the eye. Br J Physiol Opt. 1960 Oct;17:195–216. [PubMed]
  • COX, J. Colour vision defects acquired in diseases of the eye. Br J Physiol Opt. 1961 Jan;18:3–contd. [PubMed]
  • COX, J. Colour vision defects acquired in diseases of the eye. Br J Physiol Opt. 1961 Apr;18:67–concl. [PubMed]
  • COX, J. Unilateral color deficiency, congenital and acquired. J Opt Soc Am. 1961 Sep;51:992–999. [PubMed]
  • Grützner, P. Acquired color vision defects secondary to retinal drug toxicity. Ophthalmologica. 1969;158(Suppl):592–604. [PubMed]
  • Krill, AE; Fishman, GA. Acquired color vision defects. Trans Am Acad Ophthalmol Otolaryngol. 1971 75(5):1095–1111.Sep–Oct; [PubMed]
  • Nikoskelainen, E. Symptoms, signs and early course of optic neuritis. Acta Ophthalmol (Copenh). 1975 Mar;53(2):254–272. [PubMed]
  • Pinckers, A; Verriest, G. Résultats de tests cliniques de la vision des couleurs dans la sclérose en plaques. Bull Soc Belge Ophtalmol. 1982;199-200:131–144. [PubMed]
  • Tsukamoto, M; Adachi-Usami, E. [Color vision in multiple sclerosis with optic neuritis]. Nippon Ganka Gakkai Zasshi. 1987 Jun;91(6):613–621. [PubMed]
  • VERRIEST, G. Further studies on acquired deficiency of color discrimination. J Opt Soc Am. 1963 Jan;53:185–195. [PubMed]
  • Wildberger, HG; van Lith, GH. Color vision and visually evoked response (VECP) in the recovery period of optic neuritis. Mod Probl Ophthalmol. 1976;17:320–324. [PubMed]
  • Harris, GS; Yeung, J. Maculopathy of sex-linked juvenile retinoschisis. Can J Ophthalmol. 1976 Jan;11(1):1–10. [PubMed]
  • Fleishman, JA; Beck, RW; Linares, OA; Klein, JW. Deficits in visual function after resolution of optic neuritis. Ophthalmology. 1987 Aug;94(8):1029–1035. [PubMed]
  • Ménage, MJ; Papakostopoulos, D; Dean Hart, JC; Papakostopoulos, S; Gogolitsyn, Y. The Farnsworth-Munsell 100 hue test in the first episode of demyelinating optic neuritis. Br J Ophthalmol. 1993 Feb;77(2):68–74. [PubMed]
  • Hoyt, CS. The Farnsworth-Munsell 100 hue test and optic neuritis. Br J Ophthalmol. 1993 Feb;77(2):65–65. [PubMed]
  • Beck, RW. The Optic Neuritis Treatment Trial. Arch Ophthalmol. 1988 Aug;106(8):1051–1053. [PubMed]
  • Beck, RW; Cleary, PA; Anderson, MM, Jr; Keltner, JL; Shults, WT; Kaufman, DI; Buckley, EG; Corbett, JJ; Kupersmith, MJ; Miller, NR, et al. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group. N Engl J Med. 1992 Feb 27;326(9):581–588. [PubMed]
  • Beck, RW; Cleary, PA; Trobe, JD; Kaufman, DI; Kupersmith, MJ; Paty, DW; Brown, CH. The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. The Optic Neuritis Study Group. N Engl J Med. 1993 Dec 9;329(24):1764–1769. [PubMed]
  • Poser, CM; Paty, DW; Scheinberg, L; McDonald, WI; Davis, FA; Ebers, GC; Johnson, KP; Sibley, WA; Silberberg, DH; Tourtellotte, WW. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol. 1983 Mar;13(3):227–231. [PubMed]
  • Ferris, FL, 3rd; Kassoff, A; Bresnick, GH; Bailey, I. New visual acuity charts for clinical research. Am J Ophthalmol. 1982 Jul;94(1):91–96. [PubMed]
  • Knoblauch, K. On quantifying the bipolarity and axis of the Farnsworth-Munsell 100-Hue test. Invest Ophthalmol Vis Sci. 1987 Apr;28(4):707–710. [PubMed]
  • Vingrys, AJ; King-Smith, PE. A quantitative scoring technique for panel tests of color vision. Invest Ophthalmol Vis Sci. 1988 Jan;29(1):50–63. [PubMed]
  • Smith, VC; Pokorny, J; Pass, AS. Color-axis determination on the Farnsworth-Munsell 100-hue test. Am J Ophthalmol. 1985 Jul 15;100(1):176–182. [PubMed]
  • Kinnear, PR. Proposals for scoring and assessing the 100-Hue test. Vision Res. 1970 May;10(5):423–433. [PubMed]
  • Poulsen, AD. Acquired dyschromatopsias. Mod Probl Ophthalmol. 1972;11:84–93. [PubMed]
  • Han, DP; Thompson, HS; Folk, JC. Differentiation between recently resolved optic neuritis and central serous retinopathy. Use of tests of visual function. Arch Ophthalmol. 1985 Mar;103(3):394–396. [PubMed]
  • STEINMETZ, RD; KEARNS, TP. H-R-R pseudo-isochromatic plates; as a diagnostic aid in retrobulbar neuritis of multiple sclerosis. Am J Ophthalmol. 1956 May;41(5):833–837. [PubMed]
  • Mullen, KT; Plant, GT. Colour and luminance vision in human optic neuritis. Brain. 1986 Feb;109 (:1–13. [PubMed]
  • Griffin, JF; Wray, SH. Acquired color vision defects in retrobulbar neuritis. Am J Ophthalmol. 1978 Aug;86(2):193–201. [PubMed]
  • Zeller, RW. Ocular findings in the remission phase of multiple sclerosis. Am J Ophthalmol. 1967 Oct;64(4):767–772. [PubMed]
  • Engell, T; Trojaborg, W; Raun, NE. Subclinical optic neuropathy in multiple sclerosis. A neuro-ophthalmological investigation by means of visually evoked response, Farnworth-Munsell 100 Hue test and Ishihara test and their diagnostic value. Acta Ophthalmol (Copenh). 1987 Dec;65(6):735–740. [PubMed]
  • Travis, D; Thompson, P. Spatiotemporal contrast sensitivity and colour vision in multiple sclerosis. Brain. 1989 Apr;112 (:283–303. [PubMed]
  • Burde, RM; Gallin, PF. Visual parameters associated with recovered retrobulbar optic neuritis. Am J Ophthalmol. 1975 Jun;79(6):1034–1037. [PubMed]
  • Russell, MH; Murray, IJ; Metcalfe, RA; Kulikowski, JJ. The visual defect in multiple sclerosis and optic neuritis. A combined psychophysical and electrophysiological investigation. Brain. 1991 Dec;114 (:2419–2435. [PubMed]
  • Chu, FC; Reingold, DB; Cogan, DG; Hunt, SM; Young, DH. Clinical studies of color vision with Gunkel's chromagraph. Arch Ophthalmol. 1983 Aug;101(8):1232–1235. [PubMed]
  • Wildberger, H. Neuropathies of the optic nerve and visual evoked potentials with special reference to color vision and differential light threshold measured with the computer perimeter OCTOPUS. Doc Ophthalmol. 1984 Oct 31;58(2):147–227. [PubMed]
  • Hart, WM, Jr; Burde, RM. Color contrast perimetry. The spatial distribution of color defects in optic nerve and retinal diseases. Ophthalmology. 1985 Jun;92(6):768–776. [PubMed]
  • Hart, WM., Jr Acquired dyschromatopsias. Surv Ophthalmol. 1987 32(1):10–31.Jul–Aug; [PubMed]
  • Silverman, SE; Hart, WM, Jr; Gordon, MO; Kilo, C. The dyschromatopsia of optic neuritis is determined in part by the foveal/perifoveal distribution of visual field damage. Invest Ophthalmol Vis Sci. 1990 Sep;31(9):1895–1902. [PubMed]
  • Williams, DR; MacLeod, DI; Hayhoe, MM. Foveal tritanopia. Vision Res. 1981;21(9):1341–1356. [PubMed]
  • Williams, DR; MacLeod, DI; Hayhoe, MM. Punctate sensitivity of the blue-sensitive mechanism. Vision Res. 1981;21(9):1357–1375. [PubMed]
  • de Monasterio, FM; McCrane, EP; Newlander, JK; Schein, SJ. Density profile of blue-sensitive cones along the horizontal meridian of macaque retina. Invest Ophthalmol Vis Sci. 1985 Mar;26(3):289–302. [PubMed]
  • Reese, BE; Guillery, RW. Distribution of axons according to diameter in the monkey's optic tract. J Comp Neurol. 1987 Jun 15;260(3):453–460. [PubMed]
  • Dain, SJ; Rammohan, KW; Benes, SC; King-Smith, PE. Chromatic, spatial, and temporal losses of sensitivity in multiple sclerosis. Invest Ophthalmol Vis Sci. 1990 Mar 1;31(3):548–558. [PubMed]
  • Wall, M. Loss of P retinal ganglion cell function in resolved optic neuritis. Neurology. 1990 Apr;40(4):649–653. [PubMed]